RET and neuroendocrine tumors

Yoshiki Murakumo, Mayumi Jijiwa, Naoya Asai, Masatoshi Ichihara, Masahide Takahashi

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)


The RET proto-oncogene encodes a receptor tyrosine kinase that is a main component of the signaling pathway activated by the glial cell line-derived neurotrophic factor family ligands. Gene targeting studies revealed that signaling through RET plays a crucial role in neuronal and renal organogenesis. It is well-known that germline mutations in RET lead to the human inherited diseases, multiple endocrine neoplasia type 2 (MEN 2) and Hirschsprung's disease, and that somatic rearrangements of RET cause papillary thyroid carcinoma. Due to marked advances in understanding of the molecular mechanisms of the development of MEN 2, a consensus on MEN 2 management associated with RET status is being reached and currently put into general use as a guideline. In this review, we summarize progress in the study of RET from bench to bedside, focusing on pathophysiology of neuroendocrine tumors.

Original languageEnglish
Pages (from-to)179-192
Number of pages14
Issue number3
Publication statusPublished - 2006
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'RET and neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this